People In Brief

Somaxon CEO moves to Apricus; Dr. Reddy’s founder dies; Spherix science director joins ABC board; Fitness entrepreneur Weider dies; Standard Process makes promotions.

Apricus Biosciences Inc. appoints Richard Pascoe as CEO and to the board of directors. Pascoe moves from Somaxon Pharmaceuticals Inc., where as CEO he led the firm through FDA approval and commercialization of the Silenor drug indicated for insomnia and the firm’s recent sale(see “Somaxon finds buyer,” p. 8). Pascoe previously was senior VP and chief operating officer at Ariad Pharmaceuticals Inc., and senior VP of marketing and sales at King Pharmaceuticals Inc. Interim Apricus CEO Steve Martin resumes his responsibilities as senior VP and chief financial officer, the San Diego-based firm said March 18. Apricus develops OTC and Rx treatments for male and female sexual health, in transdermal, oral and subcutaneous forms ([A#05110905009]).

K. Anji Reddy, founder and chairman of Dr. Reddy's Laboratories Ltd., died March 15 in Hyderabad, India. A graduate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Some Laid Off Employees Called Back At US FDA

 

Some FDA employees who were recently laid off by the Trump Administration are being called back to work, multiple sources confirmed to the Pink Sheet.

US Proposal To Remove Phenylephrine From OTC Monograph Could Stress-Test Streamlined Process

 

Proposed administrative order likely is first to prompt opposition from OTC industry or other stakeholders potentially delaying or deferring the agency’s expectation for moving its proposal to a deemed final order effective one year after it would be published.

FDA Clears Qnovia’s NRT Inhalation IND, Commits To ‘Stimulating’ Smoking Cessation Innovation

 

Qnovia notes NRT inhalation product recently received investigational new drug clearance from FDA as agency and NIH say innovation needed smoking cessation to help improve rate of success for quitting the habit that kills around 500,000 US consumers annually.

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

More from North America

Washington State TFCA Violators Likely To Face Conversation Before Penalties – DOE

 

The Washington State Department of Ecology will try to work with companies that violate the Toxic Free Cosmetics Act, rather than reflexively imposing the $5,000-per-violation fine for first-time offenders, says the law’s implementation planner. She noted financial assistance is available for small businesses, as well as incentives for companies adopting measures “beyond compliance.”

Adcomm Reform: Getting Needed Information More Important Than Vote Or Discussion

 

US FDA Office of New Drugs Director Peter Stein says review divisions have made the case that a discussion-only meeting would solicit the necessary input.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

 

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.